{"filing":{"accession_number":"0001077183-26-000058","cik":"0001077183","ticker":"NEO","company_name":"NEOGENOMICS INC","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"neo-20260728.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718326000058/neo-20260728.htm"},"events":[{"id":21059,"run_id":18976,"accession_number":"0001077183-26-000058","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"NeoGenomics issued a press release on July 28, 2026 reporting second-quarter 2026 financial results, including revenue of $202 million (11% YoY growth), net income of $2 million, and adjusted EBITDA of $14 million (36% increase). The company also raised full-year 2026 revenue and adjusted EBITDA guidance. This is a standard quarterly earnings disclosure furnished under Item 2.02 with complete financial statements and forward-looking guidance.","company_name":"NEOGENOMICS INC","ticker":"NEO","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20593,"accession_number":"0001077183-26-000058","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"NeoGenomics issued a press release on July 28, 2026 reporting second-quarter 2026 financial results, including revenue of $202 million (11% YoY growth), net income of $2 million, and adjusted EBITDA of $14 million (36% increase). The company also raised full-year 2026 revenue and adjusted EBITDA guidance. This is a standard quarterly earnings disclosure furnished under Item 2.02 with complete financial statements and forward-looking guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:09:34.754945+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20593,"accession_number":"0001077183-26-000058","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"NeoGenomics issued a press release on July 28, 2026 reporting second-quarter 2026 financial results, including revenue of $202 million (11% YoY growth), net income of $2 million, and adjusted EBITDA of $14 million (36% increase). The company also raised full-year 2026 revenue and adjusted EBITDA guidance. This is a standard quarterly earnings disclosure furnished under Item 2.02 with complete financial statements and forward-looking guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:09:34.754945+00:00","company_name":"NEOGENOMICS INC","ticker":"NEO","filing_date":"2026-07-28"}]}